Stock Taper
TLPH
TALPHERA, INC.
NASDAQ
$1.20
▲ UP 0.00% (0.00)

KEY STATISTICS

Market Cap$62.28 M
52w High$1.57
52w Low$0.50
Dividend Yield
Frequency
P/E-3.87
Volume64.60K
Shares Out.51.90M

COMPANY

LEADERSHIP

Vincent J. Angotti
CHIEF EXECUTIVE
Vincent J. Angotti

COMPENSATION 2026

Salary$688,811
Stock Awards$35,563
Incentive Plan Pay$0
All Other Comp.$14,000
Total$1,117,277

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 11, 2011
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
12

PRICE TARGET

Target High$3.00
Target Low$3.00
Target Median$3.00
Target Consensus$3.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2022-10-26Reverse1:20

PRICE

$1.20 ▲ UP 0.00% (+$0.00)
OVERLAYS
$1.19$1.20$1.219:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.20

About Talphera, Inc.

https://talphera.com ↗

Talphera, Inc. is a California-based specialty pharmaceutical company developing therapies like Niyad, LTX-608, Fedsyra, and PFS-02 for medically supervised settings, focusing on anticoagulation, anti-inflammation, and viral conditions.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT TALPHERA, INC. IS KNOWN FOR

Niyad
Niyad

Niyad is a lyophilized nafamostat anticoagulant for extracorporeal circuits, FDA Breakthrough Designated, and Talphera's lead product, marking its shift toward innovative therapies for patients intolerant to heparin.

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

DIRECTOR
ADAMS ADRIAN
Purchase · 30.7K shares
2026-06-22
DIRECTOR
Bozilenko Marina
Purchase · 5.1K shares
2026-06-22
DIRECTOR
Broadfoot Jill Marie
Purchase · 5.1K shares
2026-06-22
DIRECTOR
Bozilenko Marina
Purchase · 30.7K shares
2026-06-22

SECTORS PEERS

PEERPRICE
NTRB$5.77COMPARE
SCYX$5.28COMPARE
MIRA$0.76COMPARE
PIII$9.00COMPARE
IBIO$1.29COMPARE
COSM$0.26COMPARE
INTS$4.06COMPARE